Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03279302 · ClinicalTrials.gov registry record · Phase 1
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
A Phase 1 study, sponsored by Zealand Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT03279302 is a Phase 1 study that has completed, run by Zealand Pharma. The registered enrollment target is 75 participants.
The verdict
NCT03279302, a Phase 1 study, has completed, sponsored by Zealand Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The primary objective of the trial is to characterize the pharmacokinetic (PK) profiles of glepaglutide and its primary active metabolites following once-daily and once-weekly subcutaneous (SC) injections and after a single intravenous (IV) infusion in healthy subjects. Glepaglutide is a proposed International Nonproprietary Name for ZP1848
Interventions
- DRUG Glepaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2017-09-04 |
| Est. Completion | 2017-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03279302
The ClinicalTrials.gov registry entry for NCT03279302 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zealand Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glepaglutide is the first listed.
NCT03279302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03279302 about?
NCT03279302 is a clinical study titled "Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects". The primary objective of the trial is to characterize the pharmacokinetic (PK) profiles of glepaglutide and its primary active metabolites following once-daily and once-weekly subcutaneous (SC) injections and after a single intravenous (IV) infusion in healthy subjects. Glepaglutide is a proposed I...
What is the current status of trial NCT03279302?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2017-09-04. Estimated completion is 2017-12-18.
What interventions are being tested in trial NCT03279302?
The interventions under investigation include: Glepaglutide (DRUG).
Who is sponsoring clinical trial NCT03279302?
This trial is sponsored by Zealand Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.